Cargando…

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on various hematological and solid tissues, while plasma cells express particularly high levels of CD38. The protein is also expressed in a subset of hematol...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Invited Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755228/ https://www.ncbi.nlm.nih.gov/pubmed/26864107 http://dx.doi.org/10.1111/imr.12389

Ejemplares similares

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
por: Hiemstra, Ida H., et al.
Publicado: (2023)

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
por: van der Veer, M S, et al.
Publicado: (2011)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
por: Overdijk, Marije B, et al.
Publicado: (2015)

Novel human antibody therapeutics: The age of the Umabs
por: Ruuls, Sigrid R, et al.
Publicado: (2008)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
por: Adams, Homer C., et al.
Publicado: (2018)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

P854: HEXABODY-CD38 INDUCES TROGOCYTOSIS AND EFFECTIVELY INDUCES COMPLEMENT-MEDIATED TUMOR CELL LYSIS AFTER TREATMENT WITH DARATUMUMAB OR ISATUXIMAB IN VITRO
por: Hiemstra, I. H., et al.
Publicado: (2022)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
por: Chatelut, Etienne, et al.
Publicado: (2021)

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
por: Stikvoort, Arwen, et al.
Publicado: (2021)

Prebiotic galactooligosaccharides activate mucin and pectic galactan utilization pathways in the human gut symbiont Bacteroides thetaiotaomicron
por: Lammerts van Bueren, Alicia, et al.
Publicado: (2017)

Structural Identity of Galactooligosaccharide Molecules Selectively Utilized by Single Cultures of Probiotic Bacterial Strains
por: Böger, Markus, et al.
Publicado: (2019)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

HIC2 regulates isoform switching during maturation of the cardiovascular system
por: Dykes, Iain M., et al.
Publicado: (2018)

Draft Genome Sequence of Lactobacillus reuteri 121, a Source of α-Glucan and β-Fructan Exopolysaccharides
por: Gangoiti, Joana, et al.
Publicado: (2017)

Corrigendum to “HIC2 regulates isoform switching during maturation of the cardiovascular system” [Journal of Molecular and Cellular Cardiology volume 114 (2018) P29-37/ https://doi.org/10.1016/j.yjmcc.2017.10.007]
por: Dykes, Iain M., et al.
Publicado: (2023)

Contemporary Monoclonal Antibody Utilization in Glomerular Diseases
por: Mansour, Iyad, et al.
Publicado: (2023)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

Towards resilience through systems-based plant breeding. A review
por: Lammerts van Bueren, Edith T., et al.
Publicado: (2018)

Toward targeting B cell cancers with CD4(+) CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis
por: Spaapen, Robbert M., et al.
Publicado: (2008)

Influence of transplant size on the above- and below-ground performance of four contrasting field-grown lettuce cultivars
por: Kerbiriou, P. J., et al.
Publicado: (2013)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response
por: Dalgleish, A, et al.
Publicado: (2014)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Effects of a recombinant humanized anti‐cocaine monoclonal antibody on the metabolism and distribution of cocaine in vitro and in mice
por: Turner, Mackenzie E., et al.
Publicado: (2022)

Basic Fibroblast Growth Factor-Mediated Overexpression of Vascular Endothelial Growth Factor in 1F6 Human Melanoma Cells is Regulated by Activation of PI-3K and p38 MAPK
por: Fontijn, Dennis, et al.
Publicado: (2009)

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS
por: Bruins, Wassilis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8onfcvf2g0dkvbqgk5llo8aac7